Back to Search Start Over

Prognostic value of serum paraprotein response kinetics in patients with newly diagnosed multiple myeloma

Authors :
Tamariz-Amador, Luis-Esteban
Rodríguez-Otero, Paula
Jiménez-Ubieto, Ana
Rosiñol, Laura
Oriol, Albert
Ríos-Tamayo, Rafael
Sureda, Anna
Blanchard, María Jesús
Hernández, Miguel Teodoro
Cabañas Perianes, Valentín
Jarque, Isidro
Bargay, Joan
Gironella, Mercedes
De Arriba, Felipe
Palomera, Luís
González-Montes, Yolanda
Martí, José M.
Krsnik, Isabel
Arguiñano, José María
González, Maríua Ester
Casado Montero, Luis Felipe
González-Rodriguez, Ana Pilar
López-Anglada, Lucía
Puig, Noemí
Cedena, María Teresa
Paiva, Bruno
Mateos, M. V
San-Miguel, J
Lahuerta, J. J
Bladé Creixenti, Juan
Trocóniz, Iñaki F.
Universitat Autònoma de Barcelona
Institut Català de la Salut
[Tamariz-Amador LE, Rodríguez-Otero P] Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain. [Jiménez-Ubieto A] Hospital 12 de Octubre, Madrid, Spain. [Rosiñol L] Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain. [Oriol A] Institut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain. [Ríos R] Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
Source :
Scientia, Clinical lymphoma, myeloma & leukemia, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
Publication Year :
2022

Abstract

Response kinetics is not well-established as a prognostic marker in multiple myeloma (MM). We developed a mathematical model to assess the prognostic value of serum monoclonal component (MC) response kinetics during 6 induction cycles in 373 newly diagnosed MM patients. The model calculated a resistance parameter that reflects the stagnation in the response after an initial descent, dividing the patients into two kinetics categories with significantly different progression-free survival (PFS). Introduction: Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). Materials and Methods: We developed a mathematical model to assess the prognostic value of serum MC response kinetics during 6 induction cycles, in 373 NDMM transplanted patients treated in the GEM2012Menos65 clinical trial. The model calculated a resistance parameter that reflects the stagnation in the response after an initial descent. Results: Two patient subgroups were defined based on low and high resistance, that respectively captured sensitive and refractory kinetics, with progression-free survival (PFS) at 5 years of 72% and 59% (HR 0.64, 95% CI 0.44-0.93; P =.02). Resistance significantly correlated with depth of response measured after consolidation (80.9% CR and 68.4% minimal residual disease negativity in patients with sensitive vs. 31% and 20% in those with refractory kinetics). Furthermore, it modulated the impact of reaching CR after consolidation; thus, within CR patients those with refractory kinetics had significantly shorter PFS than those with sensitive kinetics (median 54 months vs. NR; P =.02). Minimal residual disease negativity abrogated this effect. Our study also questions the benefit of rapid responders compared to late responders (5-year PFS 59.7% vs. 76.5%, respectively [P

Details

Language :
English
ISSN :
21522650
Database :
OpenAIRE
Journal :
Scientia, Clinical lymphoma, myeloma & leukemia, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
Accession number :
edsair.doi.dedup.....b988f31df860b307e0690fb453a3b58b